Latest news

• Low-dose LSD looks safe for Alzheimer’s patients, but will it work?

  6. -targeting drug  idalopirdine for example. The entire Alzheimer’s drug development field is littered with failed candidates, so expectations for the LSD project remain firmly in check at the time

• Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

  It’s also had some late-stage pipeline setbacks, including treatment-resistant schizophrenia therapy Lu AF35700 and Alzheimer’s candidate idalopirdine, that have left its pipeline in need of a top

• Lundbeck snaps up Abide Therapeutics for $400m

  challenging. Efforts to bring forward its own drugs have been undermined by a couple of late-stage failures, including idalopirdine for Alzheimer’s disease and Lu AF35700 for treatment-resistant schizophrenia.

• Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

  the failure of Alzheimer’s candidate idalopirdine.

• Axovant joins ever-growing Alzheimer’s failure club

  5-HT6 inhibitor Intepirdine followsin the footsteps of Lundbeck's idalopirdine. Axovant’s phase III trial of Alzheimer’s disease (AD) candidate intepirdine has ended in failure, an outcome that ... s idalopirdine, which suffered a similar late-stage